{"nctId":"NCT00591006","briefTitle":"Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes","startDateStruct":{"date":"2008-01"},"conditions":["Healthy"],"count":17,"armGroups":[{"label":"Four Treatments Per Participant","type":"EXPERIMENTAL","interventionNames":["Drug: Phenytoin (brand name Dilantin)","Drug: Hydrocortisone","Drug: Placebo"]}],"interventions":[{"name":"Phenytoin (brand name Dilantin)","otherNames":["5,5-Diphenylhydantoin","Fenitoin","Antisacer","Difenin","Dihydan","Dilantin","Diphenylhydantoin","Epamin","Hydantol","Sodium Diphenylhydantoinate"]},{"name":"Hydrocortisone","otherNames":["Cortef","Corticosteroids"]},{"name":"Placebo","otherNames":["Sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18-50 years\n* Men or women\n* Vision corrected to at least 20-40\n* No tobacco use\n* Education of ≥12 years (No GED)\n\nExclusion Criteria:\n\n* History of major psychiatric illness defined as major depressive disorder, bipolar disorder, post traumatic stress disorder, panic disorder, schizoaffective disorder, schizophrenia or eating disorders\n* History of drug or alcohol abuse or dependence\n* History of neurological disorders including seizures, brain surgery, multiple sclerosis, Parkinson's disease\n* Taking central nervous system (CNS) acting medications (e.g. antidepressants, hypnotics)\n* History of allergic reaction or medical contraindication to phenytoin or hydrocortisone therapy\n* Metal implants, claustrophobia or other contraindications to MRI\n* Significant medical conditions (e.g. myocardial infarction, diabetes)\n* Pregnant or nursing women\n* Prisoners\n* History of mental retardation, special education classes, dementia or other severe cognitive disorders\n* Baseline Hamilton Rating Scale for Depression Score \\> 7\n* History of a suicide attempt\n* History of systemic corticosteroid use or current inhaled corticosteroid use","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Difference in RAVLT Total T-Score Between Treatments","description":"The Rey Auditory Verbal Learning Test (RAVLT) evaluates a wide diversity of functions, including short-term auditory-verbal memory, and retention of information. Test raw scores are converted to T-scores. T-scores have a mean of 30 ± 10 where higher scores are indicative of better verbal memory. Total T-score differences following study treatment interventions are reported.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.76","spread":"0.51"},{"groupId":"OG001","value":"56.11","spread":"0.67"},{"groupId":"OG002","value":"53.08","spread":"0.45"},{"groupId":"OG003","value":"42.76","spread":"2.60"}]}]}]},{"type":"SECONDARY","title":"Hippocampal Activation Differences Between Treatment Conditions","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.035","spread":"0.180"},{"groupId":"OG001","value":"1.288","spread":".06"},{"groupId":"OG002","value":"1.135","spread":"0.161"},{"groupId":"OG003","value":"1.121","spread":"0.144"}]}]}]},{"type":"SECONDARY","title":"Para-Hippocampal Activation Differences Between Treatment Conditions","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.293","spread":"0.264"},{"groupId":"OG001","value":"1.604","spread":"0.315"},{"groupId":"OG002","value":"1.464","spread":"0.246"},{"groupId":"OG003","value":"1.401","spread":"0.202"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":16},"commonTop":[]}}}